Simvastatin & Rifaximin for Cirrhosis: Improved Outcomes?
Simvastatin adn Rifaximin in Decompensated Cirrhosis: Reconciling Conflicting Trial Results The management of decompensated cirrhosis remains a significant challenge in hepatology. Recent findings from the LIVERHOPE study,published in July 2025,have sparked debate regarding the efficacy of simvastatin and rifaximin in improving outcomes for these patients. the study indicated no discernible difference in the occurrence of … Read more